Editorial: Global research priorities for antimicrobial resistance in human health: evidence and innovation towards WHO agenda 2030
Frontiers in Pharmacology · 20.11.2026 · 17
DOI: 10.3389/fphar.2026.2052958 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 20.11.2026. Verfasst von Zikria Saleem und 2 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Two cohort studies from China quantify the extent to which multidrug-resistant organism (MDRO) infections cost patients and health systems. Yan et al. (2026) found that hospitalacquired MDRO infection in gastrointestinal-surgery patients added a median of nearly 47,000 CNY (approximately US$7,000) in hospitalization costs and approximately six additional ICU days. Cheng et al. (2026) followed 388 ICU patients, a quarter of whom were colonized with MDROs, chiefly ESBL-producing Klebsiella pneumoniae and Escherichia coli and MRSA.Colonization and comorbidities, including diabetes, independently predicted infection within 28 days. Underpinning such evidence, Chethrapilly Purushothaman et al. ( 2026) report operational lessons from implementing community and hospital intestinal-colonization surveillance in India, a reminder that credible AMR data in low-resource settings depend on adaptable, contextsensitive study designs. Three studies examine why antimicrobials are used inappropriately, a key driver of AMR (Abejew et al., 2024;Wang et al., 2025). Gaps in healthcare students' knowledge of antimicrobials, AMR and antimicrobial stewardship (AMS) matter because they shape future prescribing and dispensing once qualified (Saleem et al., 2025;Cook et al., 2026). Among 288 Zambian pharmacy students, Mudenda et al. (2026) found that although 94.1% could define antifungal resistance and 67.7% held positive attitudes, only 18.1% showed good overall knowledge and just 2.4% practiced appropriately. Together with earlier studies among Zambian pharmacy students on antibiotics, AMR and prevention practices, these findings point to the need for stronger curricular and experiential training on antimicrobials, including antifungals, and AMR, especially in LMICs (Mudenda et al., 2023).In rural South Africa, Maluleke et al. (2026) showed that patients generally understood that antibiotic overuse drives AMR. However, concerns remained regarding antibiotic overprescribing for acute respiratory infections, with community pharmacists usually offering symptomatic relief, and patients typically visiting them first for sexually transmitted infections (STIs). Community pharmacy personnel could therefore become more involved in preventing and managing infectious diseases, including STIs, building on experiences elsewhere (Hedima and Okoro, 2025;Maluleke et al., 2025). When developing and applying the Community Antimicrobial Use Scale (CAMUS), Ramdas et al. (2026) found that non-prescribed antibiotic use, reported by nearly a quarter of participating patients, was driven less by factual knowledge gaps than by permissive social norms and limited health literacy. This is important because patients in LMICs frequently request antibiotics from prescribers and dispensers, often for viral, self-limiting infections (Ramdas et al., 2025;Saleem et al., 2025). Together, these studies argue that educational and subsequent AMS activities must target patient and healthcare professional behavior, building on a robust knowledge base. Three papers address how antimicrobials are prescribed. Wang et al. (2026) presented a protocol for a multicenter, interrupted time series study of a bundled AMS intervention (including earlyonset sepsis risk stratification and mandatory 48-72-hour antibiotic reassessment) across neonatal intensive care units in resource-limited regions of China. In a network meta-analysis of 64 randomized trials, Sun et al. ( 2026) compared 24 antibiotics for group A streptococcal pharyngitis and found that cefdinir and cefpodoxime proxetil outperformed penicillin V for early bacterial eradication, whereas azithromycin was inferior. Extending AMS activities to pediatric pneumonia, Zhou et al. (2026) reported that short-course oral antibiotic therapy was not associated with increased treatment failure compared with standard or longer courses. These findings support infection-specific shortening of treatment duration, which is important in LMICs where there are high co-payments for antibiotics. Two contributions push the innovation agenda forward. Alnezary and Almutairi (2026) validated a standardized Galleria mellonella larval model of Clostridioides difficile infection, offering an ethical, low-cost, and reproducible alternative to mammalian models for evaluating pathogenesis and treatment efficacy. Drawing on microbiological studies at the Uganda Cancer Institute since 2014, Lubwama et al. ( 2026) argued in a policy brief that infectious-diseases expertise must be integrated into the care of cancer patients in sub-Saharan Africa, where patients are 1.5-2 times more likely to be affected by AMR and guidelines often derive from high-income settings that may not match local resistance profiles. Such local adaptation is also important when applying the WHO Access, Watch, Reserve (AWaRe) antibiotic book to improve patient management (Jamil et al., 2025a), seen as robust given concerns that national antibiotic guidelines, especially in LMICs, often recommend Watch antibiotics heavily (Jamil et al., 2025b;Arooj et al., 2026). The final cluster reflects the emphasis of the updated Global Action Plan on infection prevention and control, water, sanitation and hygiene (WASH), and One Health action (World Health Organization, 2026). Saleem (2026) reviewed integrated WASH and infection prevention strategies in Pakistan, finding growing but urban-concentrated evidence and persistent policypractice gaps under the National Action Plan. Qashqari (2026) surveyed 712 Hajj pilgrims over three seasons: 38.9% reported respiratory symptoms, empirical antibiotic use was frequent for largely viral presentations, and influenza vaccination appeared protective. These findings can help improve preventive measures among pilgrims and reduce inappropriate antibiotic use and associated AMR. Finally, among 450 Saudi university students, Alnezary et al. ( 2026) found that perceived barriers, rather than perceived benefits, were the strongest predictor of influenza vaccine hesitancy. These barriers need to be addressed to encourage vaccination as an AMRprevention tool. Read together, the 14 articles map onto the core functions of the global response to AMR (Figure 1): surveillance and burden estimation, responsible antimicrobial use, optimized therapy, prevention, and innovation. Their geographic center of gravity, including China, India, Pakistan, Zambia, South Africa, and Uganda, mirrors where the AMR burden, and the opportunity for impact, is greatest. Three themes recur: inappropriate antimicrobial use is shaped as much by access and social norms as by knowledge, including knowledge of all key stakeholder groups; colonization surveillance and economic evidence strengthen the case for investing in infection prevention; and low-cost innovations, from preclinical models to AMS activities, matter most where resources are constrained. Priorities therefore include ensuring that all trainee healthcare professionals, especially those about to start practicing, are fully conversant with antibiotics, AMR, AMS and preventive practices. This has not always been the case (Mudenda et al., 2023;Saleem et al., 2025). However, notable gaps remain. There were few contributions addressing environmental or agricultural reservoirs, underscoring the need for One Health research that links human, animal, and environmental resistance data to improve future antibiotic use across all sectors. Long-term outcomes, including mortality, readmission, and costs beyond index hospitalization, are scarce. Such evidence should grow with greater use of quality indicators across all sectors to improve future antibiotic use and outcomes as part of AMS programs (Heath et al., 2025). Research on sustainable financing for national action plans, which many LMICs have adopted but struggle to fund, is also limited. As the 2030 milestones approach, closing these gaps will require sustained investment in the locally grounded, cross-disciplinary evidence that this Research Topic represents. We look forward to future research covering these topics.We thank all authors and reviewers for their contributions.
Zitieren
APA
Saleem, Z., Godman, B., & Mudenda, S. (2026). Editorial: Global research priorities for antimicrobial resistance in human health: evidence and innovation towards WHO agenda 2030. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.2052958
Vancouver
Saleem Z, Godman B, Mudenda S. Editorial: Global research priorities for antimicrobial resistance in human health: evidence and innovation towards WHO agenda 2030. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.2052958
BibTeX
@article{Saleem2026,
author = {Saleem, Zikria and Godman, Brian and Mudenda, Steward},
title = {Editorial: Global research priorities for antimicrobial resistance in human health: evidence and innovation towards WHO agenda 2030},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.2052958}
}
EUVIMED